ArticleFrontiers in bioinformatics2025
Integrated multi-optosis model for pan-cancer candidate biomarker and therapy target discovery.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A pan-cancer atlas of metabolic regulatory circuitries integrating multi-omic, immune, and clinical dimensions.Frontiers in molecular biosciences · 2026Article
- A pan-cancer multi-omicFrontiers in artificial intelligence · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulated cell death (RCD) is fundamental to tissue homeostasis and cancer progression, influencing therapeutic responses across tumor types. Although individual RCD forms have been extensively studied, a comprehensive framework integrating multiple RCD processes has been lacking, limiting systematic biomarker discovery. To address this gap, we developed a multi-optosis model that incorporates 25 distinct RCD forms and integrates multi-omic and phenotypic data across 33 cancer types. This model enables the identification of candidate biomarkers with translational relevance through genome-wide significant associations. We analyzed 9,385 tumor samples from The Cancer Genome Atlas (TCGA) and 7,429 non-tumor samples from the Genotype-Tissue Expression (GTEx) database, accessed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.